New drug to reduce side effects of chemo and radiation for lung cancer
Part of Cancer clinical trials.
This trial tests a drug called sodium glycididazole to see if it can reduce the side effects of standard chemo and radiation therapy in people with certain types of non-small cell lung cancer that cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer.
- Your cancer is stage II or III and could not be removed by surgery after initial treatment.
- You are well enough to be up and about at least half the day (ECOG score 0, 1, or 2).
- Your liver, kidneys, and bone marrow are working well enough.
- You have not had radiation therapy before.
- You have not had severe lung inflammation from previous immunotherapy.
- You do not have any other active cancer.
- You do not have a weakened immune system from birth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—golidocitinib (a targeted pill) and sintilimab (an immunotherapy)—for people with advanced non-small cell lung cancer that has a high PD-L1 protein level. It may offer a new option if you haven't had immunotherapy before.
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
This trial tests a combination of golidocitinib (a targeted pill) and an immunotherapy drug (anti-PD-1) for people with non-small cell lung cancer that has come back or spread after prior treatment. It aims to see if this new combination can shrink tumors or stop them from growing.
Hear when a new Chemoradiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.